Clinical performance of a device that applies local heat to the insulin infusion site: A crossover study

Journal of Diabetes Science and Technology

Volumn 6, Issue 2, 2012, Pages 320-327

  Freckmann, Guido ^a   Pleus, Stefan ^a   Westhoff, Antje ^a   Krinelke, Lars G ^b   Buhr, Andreas ^b   Jendrike, Nina ^a   Haug, Cornelia ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Roche Diabetes Care AG   (Switzerland)

Author keywords

Blood glucose; Continuous subcutaneous insulin infusion; Insulin pump; Postprandial excursion; Skin heating

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLULISINE; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABRASION; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE METER; BLOOD SAMPLING; BODY MASS; CAPILLARY BLOOD; CLINICAL ARTICLE; CROSSOVER PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEAT; HEATING; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN SENSITIVITY; MALE; MEDICAL DEVICE; PATIENT COMPLIANCE; RISK ASSESSMENT; SKIN HEATING DEVICE; SKIN MANIFESTATION; SKIN TEMPERATURE; TRANSDERMAL PATCH; VENOUS BLOOD; ADOLESCENT; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EQUIPMENT DESIGN; GERMANY; HYPERTHERMIC THERAPY; INSTRUMENTATION; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; SKIN ABSORPTION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTHERMIA, INDUCED; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN INFUSION SYSTEMS; INSULIN, SHORT-ACTING; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SKIN ABSORPTION; SKIN TEMPERATURE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865120499     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600215     Document Type: Article

References (41)

1. The efect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
2. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med. 1998;15(3):188-93. (Pubitemid 28126152)
3. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13(9):923-54. (Pubitemid 20260734)
4. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-83. (Pubitemid 40096614)
5. Fedutes BA, Calabrese Donihi A, Culley CM, McCreery BJ, Ansani NT. An Evidence-Based Summary of Insulin Analogues. Pharmacy & Therapeutics. 2005;30(2):112-20.
6. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180(4):385-97.
7. Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther. 2003;5(1):57-66. (Pubitemid 36506091)
8. Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber JP. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998;21(6):977-82. (Pubitemid 28488791)
9. Edelman SV and Morello CM. Strategies for insulin therapy in type 2 diabetes. South Med J. 2005;98(3):363-371. (Pubitemid 40381716)
10. Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc. 2009;109(1):26-36.
11. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial state in Type 2 diabetes and endothelial dysfunction: efects of insulin aspart. Diabet Med. 2004;21(2):171-5. (Pubitemid 38221817)
12. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care. 2002;25(8):1439-43. (Pubitemid 41071158)
13. Edsberg B, Herly D, Hildebrandt P, Kühl C. Insulin bolus given by sprinkler needle: efect on absorption and glycaemic response to a meal. Br Med J (Clin Res Ed). 1987;294(6584):1373-6. (Pubitemid 17078937)
14. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28(5):1077-82. (Pubitemid 40616616)
15. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS 2nd, Heinemann L, Batycky RP, Muchmore DB. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care. 2005;28(10):2400-5. (Pubitemid 41384284)
16. Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther. 2011;13(4):435-42. Epub 2011 Feb 28.
17. Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, Chase HP. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12(3):173-7.
18. Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med. 1995;12(5):449-50.
19. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43(2):137-42. (Pubitemid 29155658)
20. Müller N, Kloos C, Frank T, Ristow M, Wolf G, Müller UA. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes. Diabet Med. 2011;28(2):223-6.
21. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23(1):1-12.
22. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934-9.
23. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003;4(6):291-7. (Pubitemid 37013019)
24. Ciccone CD. Basic pharmacokinetics and the potential efect of physical therapy interventions on pharmacokinetic variables. Phys Ther. 1995;75(5):343-51.
25. Danon A, Ben-Shimon S, Ben-Zvi Z. Efect of exercise and heat exposure on percutaneous absorption of methyl salicylate. Eur J Clin Pharmacol. 1986;31(1):49-52. (Pubitemid 16017451)
26. Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J. 1980;280(6229):1411-3. (Pubitemid 10123127)
27. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Efect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia. 1994;37(4):377-80. (Pubitemid 24113569)
28. Dillon RS. Improved serum insulin profiles in diabetic individuals who massaged their insulin injection sites. Diabetes Care. 1983;6(4):399-401. (Pubitemid 13078724)
29. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther. 2009;31(5):980-7.
30. Cengiz E, Tamborlane W, Sherr J, Martin M, Carria L, Sikes K, Urban A, Bitton G, Weinzimer S. O-11 Efect of a novel warming device on pharmacodynamics (PD) of rapid acting insulin in youth with type 1 diabetes (T1D). Abstracts. Diabetes Technol Ther. 2011;13(2):173-293.
31. Cengiz E, Tamborlane WV, Sherr JL, Martin M, Carria L, Sikes KA, Urban AD, Bitton G, Weinzimer SA. Investigating the efect of a novel warming device on the pharmacodynamics and pharmacokinetics of rapid-acting insulin in youth with type 1 diabetes. J Diabetes Sci Technol. 2011;5(2):466-A172.
32. Energy and protein requirements. Report of a joint FAO/WHO/ UNU Expert Consultation. World Health Organ Tech Rep Ser. 1985;724:1-206.
33. Le Floch JP, Escuyer P, Baudin E, Baudon D, Perlemuter L. Blood glucose area under the curve. Methodological aspects. Diabetes Care. 1990;13(2):172-5. (Pubitemid 20056207)
34. .Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Gof DV. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34(3):362-6. (Pubitemid 11159124)
35. Peters AL, Davidson MB. Protein and fat efects on glucose responses and insulin requirements in subjects with insulin-dependent diabetes mellitus. Am J Clin Nutr. 1993;58(4):555-60. (Pubitemid 23307416)
36. Pañkowska E, Szypowska A, Lipka M, Szpotañska M, Błazik M, Groele L. Application of novel dual wave meal bolus and its impact on glycated hemoglobin A1c level in children with type 1 diabetes. Pediatr Diabetes. 2009;10(5):298-303. Epub 2008 Oct 20.
37. Jarrett RJ, Keen H. Diurnal variation of oral glucose tolerance: a possible pointer to the evolution of diabetes mellitus. Br Med J. 1969;2(5653):341-4.
38. Service FJ, Rizza RA, Hall LD, Westland RE, O'Brien PC, Clemens AH, Haymond MW, Gerich JE. Prandial insulin requirements in insulin-dependent diabetics: efects of size, time of day, and sequence of meals. J Clin Endocrinol Metab. 1983;57(5):931-6. (Pubitemid 14204289)
39. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-6. (Pubitemid 29418246)
40. Heise T, Nosek L, Spitzer H, Heinemann L, Niemöller E, Frick AD, Becker RH. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9(5):746-53. Epub 2007 Jun 26.
41. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care. 2008;31(6):1112-7. Epub 2008 Mar 13.